MARKSANS Stock Overview
Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Marksans Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹174.30 |
| 52 Week High | ₹185.50 |
| 52 Week Low | ₹70.55 |
| Beta | 1.6 |
| 1 Month Change | 24.50% |
| 3 Month Change | 11.37% |
| 1 Year Change | 123.89% |
| 3 Year Change | 147.59% |
| 5 Year Change | 617.28% |
| Change since IPO | -35.91% |
Recent News & Updates
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Recent updates
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19Marksans Pharma Limited's (NSE:MARKSANS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Nov 04If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Oct 20Is Marksans Pharma Limited's (NSE:MARKSANS) Shareholder Ownership Skewed Towards Insiders?
Oct 05If You Had Bought Marksans Pharma (NSE:MARKSANS) Shares A Year Ago You'd Have Earned273% Returns
Sep 20A Look At The Fair Value Of Marksans Pharma Limited (NSE:MARKSANS)
Aug 20Many Still Looking Away From Marksans Pharma Limited (NSE:MARKSANS)
Aug 05If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Jul 08Shareholder Returns
| MARKSANS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 7.0% | -2.5% | -2.5% |
| 1Y | 123.9% | 55.2% | 44.5% |
Return vs Industry: MARKSANS exceeded the Indian Pharmaceuticals industry which returned 55.2% over the past year.
Return vs Market: MARKSANS exceeded the Indian Market which returned 44.5% over the past year.
Price Volatility
| MARKSANS volatility | |
|---|---|
| MARKSANS Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: MARKSANS has not had significant price volatility in the past 3 months.
Volatility Over Time: MARKSANS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 852 | Mark Saldanha | marksanspharma.com |
Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Marksans Pharma Limited Fundamentals Summary
| MARKSANS fundamental statistics | |
|---|---|
| Market cap | ₹77.24b |
| Earnings (TTM) | ₹3.16b |
| Revenue (TTM) | ₹21.03b |
25.0x
P/E Ratio3.8x
P/S RatioIs MARKSANS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MARKSANS income statement (TTM) | |
|---|---|
| Revenue | ₹21.03b |
| Cost of Revenue | ₹10.31b |
| Gross Profit | ₹10.72b |
| Other Expenses | ₹7.56b |
| Earnings | ₹3.16b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.98 |
| Gross Margin | 50.99% |
| Net Profit Margin | 15.04% |
| Debt/Equity Ratio | 5.9% |
How did MARKSANS perform over the long term?
See historical performance and comparison